Indications for Computed Tomography in Patients With Minor Head Injury
NEJM 343:100-105,138, Haydel,M.J. et al, 2000
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke
Stroke 46:2591-2598, Ganesalingam, J.,et al, 2015
Hypoglossal-Nerve Stimulation for Obstructive Sleep Apnea
NEJM 370:170-171, Malhotra, A., 2014
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
The SANAD Study of Effectiveness of Carbamazepine,Gabapentin,Lamotrigine,Oxcarbazepine,or Topiramate for Treatment of Partial Epilepsy:An Unblinded Randomised Controlled Trial
Lancet 369:1000-1015, Marson,A.G.,et al, 2007
Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
Neurol 68:1249-1250,1245, Liow,K.,et al, 2007
Long-Term Outcome After Thrombolysis in Telemedical Stroke Care
Neurol 69:898-903,819, Schwab,S.,et al, 2007
Assessment of Declofenac or Spinal Manipulative Therapy, Or Both, in Addition to Recommended First-Line Treatment for Acute Low Back Pain: A Randomised Controlled Trial
Lancet 370:1638-1643, Hancock,M.J., et al, 2007
Randomised Controlled Trial of a Short Course of Traditional Acupuncture Compared with Usual Care for Persistent Non-Specific Low Back Pain
BMJ 333:623-626,611, Thomas,K.J.,et al, 2006
Risk of Hemorrhagic Stroke With Aspirin Use
Stroke 36:1801-1807, Gorelick,P.B. &Weisman,S.M., 2005
The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Steroid Treatment for Myasthenia Gravis
Muscle Nerve 25:115-121, Rivner,M.H., 2002
Intravenous Immunoglobulin in Neurological Disease: A specialist Review
JNNP 72:440-448, Wiles,C.M.,et al, 2002
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
AGGRENOX: A Combination of Antiplatelet Drugs for Stroke Prevention
The Medical Letter 442:11-12, , 2000
New Drugs:Which Should Be Included in the Formulary?, Epilepsy:All New Drugs Should Be Included
Arch Neurol 57:272-273,275, Pierre-Louis,S.J.C., 2000
Restrictions on the Availability of Antiepileptic Drugs
Arch Neurol 57:273-274,275, Bergen,D.C., 2000
Two New Drugs for Epilepsy
The Medical Letter, 42:33-35, , 2000
Thienopyridines or Aspirin to Prevent Stroke and Other Serious Vascular Events in patients at High Risk of Vascular Disease?
Stroke 31:1779-1784, Hankey,G.J. et al, 2000
Treatment of Acute Ischemic Stroke
NEJM 343:710-722, Brott, T. & Bogousslavsky, J., 2000
Cost-Effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack
Arch Int Med 160:2773-2778, Sarasin,F.P.,et al, 2000
Zonisamide (Zonegran) for Epilepsy
The Medical Letter 42:94-95, , 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
Surgical and Endovascular Treatment of Unruptured Cerebral Aneurysms at University Hospitals
Neurol 52:1799-1805, Johnston,S.C.,et al, 1999
Therapeutic Benefit, Aspirin Revisited in Light of the Introduction of Clopidogrel
Stroke 30:1716-1721, Gorelick,P.B.,et al, 1999
Treatment and Secondary Prevention of Stroke:Evidence, Costs, and Effects on Individuals and Populations
Lancet 354:1457-1463, Hankey,G.J.&Warlow,C.P., 1999
Efficacy & Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain
Arch Neurol 55:210-217, Lipton,R.B.,et al, 1998
Cost-Effectiveness of Anticoagulation in Nonrheumatic A Fib in the Primary Prevention of Ischemic Stroke
Stroke 29:1827-1832, Lightowlers,S.&McGuire,A., 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Do New Antiepileptic Drugs Justify Their Expense
Arch Neurol 55:1140-1142, Chadwick,D., 1998
A Comparison of Rectal Diazepam Gell and Placebo for Acute Repetitive Seizures
NEJM 338:1869-1875, 19161998., Dreifuss,F.E.,et al, 1998
The Antiplatelet Effects of Ticlopidine and Clopidogrel
Ann Int Med 129:394-405, Sharis,P.J.,et al, 1998
A 55-Year-Old Man with Attention-Deficit/Hyperactivity Disorder
JAMA 280:1086-1092, Biederman,J., 1998
Tolterodine for Overactive Bladder
The Medical Letter 40:101-102, , 1998
Parenteral Fosphenytoin:Efficacy and Economic Considerations
The Neurologist 4:S30-S34, Ramsay,R.E.&Wilder,B.J., 1998
Treating Repetitive Seizures with a Rectal Diazepam Formulation,A Randomized Study
Neurol 51:1274-1282, Cereghino,J.J.,et al, 1998